HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer - Takeaway - MDSpire
From the Journals
Clinical Guidelines

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...

Share

  • 1

    Tucatinib significantly improves progression-free survival for HER2-positive MBC.

  • 2

    Study involved a randomized, double-blind phase III trial design.

  • 3

    Median progression-free survival: 24.9 months with tucatinib vs 16.3 months without.

  • 4

    Safety profile consistent with known toxicities.

  • 5

    54% of tucatinib patients remained on treatment at follow-up.

  • 6

    Benefits noted across all subgroups, including those with brain metastases.

  • 7

    High rates of manageable grade 3 adverse events.

Original Source(s)

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

  • by The ASCO Post Staff

  • April 3, 2026

Related Content

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individ...

FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL

The CAR T-cell therapy brexucabtagene autoleucel (Tecartus) was issued full approval for adult patients with relapsed or refractory mantle cell lymphoma (MCL). The approval now includes efficacy, safe...

Turning Proteins into DNA for Ultra-Sensitive Sequencing

Stanford researchers repurpose DNA sequencing technology to read proteins at single-molecule resolution, complementing – and potentially surpassing – mass spectrometry

  • April 2, 2026

  • 2 min